A Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell Non-Hodgkin Lymphoma (NHL)

Trial Profile

A Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell Non-Hodgkin Lymphoma (NHL)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs DI Leu16 IL2 (Primary)
  • Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Alopexx Oncology
  • Most Recent Events

    • 06 Dec 2016 Results (n=22) reporting maximum tolerated dose, optimal biologic dose and recommended phase 2 dose of subcutaneously administered DI-Leu16-IL2 in patients with relapsed or refractory CD20+ B-cell lymphoma, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Dec 2016 Results of phase I trial were presented at the 58th annual American Society of Hematology (ASH) meeting, according to an Alopexx media release
    • 06 Dec 2016 Results of phase I trial published in Alopexx media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top